혈우병 A 치료 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 치료 유형별, 투여 경로별, 유통 채널별, 지역별, 경쟁 시장별(2020-2030년)

Hemophilia A Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By Route of Administration, By Distribution Channel, By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,440,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,871,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,449,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

혈우병 A 치료 세계 시장 규모는 2024년 95억 1,000만 달러에서 2030년에는 약 136억 8,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 연평균 성장률(CAGR)은 6.22%를 보일 것으로 예측됩니다.

이 시장은 혈액응고 제8인자 결핍으로 인한 희귀 유전성 질환인 혈우병 A 진단을 받은 환자들의 특수한 요구를 충족시키는 광범위한 의약품 및 헬스케어 시장의 중요한 한 부분을 형성하고 있습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	95억 1,000만 달러
시장 규모 : 2030년	136억 8,000만 달러
CAGR : 2025-2030년	6.22%
급성장 부문	온라인 약국
최대 시장	북미

이 시장은 혈우병 A와 관련된 생명을 위협할 수 있는 합병증을 예방하고 관리하기 위한 종합적인 치료 솔루션을 포함하고 있습니다. 주요 성장 요인 중 하나는 전 세계적으로 혈우병 A의 유병률 증가와 진단 능력의 향상입니다. 유전학적 및 분자생물학적 진단에 대한 인식이 향상되고 개선되면서 더 많은 환자들이 정확한 진단을 받을 수 있게 되었고, 이에 따라 고급 치료 옵션에 대한 수요가 증가하고 있습니다.

기존 치료법은 혈장 또는 유전자 재조합 혈액응고 제8인자의 정맥 투여가 주류를 이루었습니다. 그러나 유전자 치료와 비인자 보충요법을 필두로 한 차세대 치료법이 주목받으면서 시장은 큰 전환기를 맞이하고 있습니다. 특히 유전자 치료는 질병의 근본적인 유전적 원인을 타겟팅하여 장기적 또는 치료적 결과를 가져올 수 있는 가능성을 제공함으로써 변화의 가능성을 가지고 있습니다.

시장 성장 촉진요인

유병률 증가 및 진단 개선

주요 시장 이슈

치료비 폭등

주요 시장 동향

유전자 치료의 등장

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 혈우병 A 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별(인자 보충 요법, 비인자 보충 요법, 유전자 치료)
  • 투여 경로(정맥내, 경구, 경비)
  • 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵
  • 치료 유형별
  • 투여 경로별
  • 유통 채널별
  • 지역별

제5장 아시아태평양의 혈우병 A 치료 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 치료 유형별
  • 투여 경로별
  • 유통 채널별
  • 국가별
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 호주
  • 일본
  • 한국

제6장 유럽의 혈우병 A 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제7장 북미의 혈우병 A 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
  • 치료 유형
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제8장 남미의 혈우병 A 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제9장 중동 및 아프리카의 혈우병 A 치료 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제10장 시장 역학

• 성장 촉진요인
• 과제

제11장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제12장 세계의 혈우병 A 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제14장 경쟁 구도

• Takeda Pharmaceutical Company Limited
• Sanofi Corporation
• Genentech USA, Inc.
• Novo Nordisk
• Pfizer Inc.
• CSL Behring LLC.
• Grifols
• Sagent Pharmaceuticals
• Octapharma USA Inc.
• UBI Pharma Inc

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH

영문 목차

영문목차

Global Hemophilia A Treatment Market was valued at USD 9.51 billion in 2024 and is projected to reach approximately USD 13.68 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.22% during the forecast period. This market forms a vital part of the broader pharmaceutical and healthcare landscape, addressing the specific needs of individuals diagnosed with Hemophilia A-a rare genetic disorder resulting from a deficiency in clotting factor VIII.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 9.51 Billion
Market Size 2030	USD 13.68 Billion
CAGR 2025-2030	6.22%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America

The market encompasses a comprehensive range of therapeutic solutions aimed at preventing and managing the potentially life-threatening complications associated with Hemophilia A. One of the key growth drivers is the rising global prevalence of the disorder, coupled with increasing diagnostic capabilities. Enhanced awareness and improvements in genetic and molecular diagnostics have led to a greater number of individuals being accurately diagnosed, thereby fueling demand for advanced treatment options.

Traditional treatment modalities have predominantly relied on intravenous administration of clotting factor VIII, derived either from plasma or recombinant sources. However, the market is undergoing a significant transformation, with growing emphasis on next-generation therapies-notably gene therapy and non-factor replacement treatments. Gene therapy, in particular, holds transformative potential by targeting the root genetic cause of the disease, offering the possibility of long-term or even curative outcomes.

Key Market Drivers

Rising Prevalence and Improved Diagnosis

The growth of the Hemophilia A Treatment Market is closely linked to the increasing prevalence of the disorder and advancements in diagnostic methodologies. Hemophilia A continues to pose a considerable public health burden. According to the World Federation of Hemophilia (WFH), an estimated 179,703 individuals worldwide had been identified with Hemophilia A as of 2023. This increase is largely attributable to greater public awareness, improved diagnostic tools, and expanded genetic testing.

The WFH has outlined a five-year strategic objective (2020-2025) to increase global diagnosis by 60,000 cases, reflecting a 25% growth. Enhanced diagnostic capabilities, including molecular and genetic testing, now allow for earlier and more accurate detection of the disorder. Early diagnosis enables personalized treatment approaches, thereby improving patient outcomes and driving innovation in the development of gene-targeted therapies.

In a landmark development, the U.S. Food and Drug Administration (FDA) approved Roctavian in June 2023-the first AAV-based gene therapy for adults with severe Hemophilia A-marking a major milestone in therapeutic advancements.

Key Market Challenges

High Cost of Treatment

The high cost of treatment remains a significant barrier to widespread adoption and accessibility within the Hemophilia A Treatment Market. Managing the disorder requires lifelong therapeutic intervention, placing a substantial financial burden on both patients and healthcare systems.

One of the principal cost drivers is factor replacement therapy, which involves complex and costly manufacturing processes. Patients often require frequent infusions-sometimes multiple times per week-exacerbating the financial strain. While extended half-life products offer the benefit of reduced infusion frequency, their higher price point offsets potential savings.

Gene therapy, although promising, also introduces new cost challenges. The production of viral vectors and genetic manipulation processes involved in gene therapy are resource-intensive, resulting in exceptionally high treatment costs. These economic factors present a major constraint on broader market accessibility and adoption.

Key Market Trends

The Emergence of Gene Therapy

Gene therapy is revolutionizing the treatment paradigm for Hemophilia A. By introducing functional factor VIII genes into the patient's cells, gene therapy targets the genetic basis of the disorder and offers a potential long-term or curative solution.

This therapeutic approach eliminates or significantly reduces the need for regular factor infusions, thereby improving patients' quality of life and easing the treatment burden. Gene therapy has demonstrated promising results in clinical trials, showing the ability to sustain elevated levels of factor VIII and reduce the incidence of spontaneous bleeding episodes.

Furthermore, gene therapy addresses several of the chronic challenges associated with traditional treatments, such as inhibitor development and treatment non-compliance. Its one-time or infrequent dosing regimen enhances patient adherence and convenience, making it a game-changing development in the market.

Key Market Players

• Takeda Pharmaceutical Company Limited
• Sanofi Corporation
• Genentech USA, Inc.
• Novo Nordisk
• Pfizer Inc.
• CSL Behring LLC.
• Grifols
• Sagent Pharmaceuticals
• Octapharma USA Inc.
• UBI Pharma Inc.

Report Scope:

In this report, the Global Hemophilia A Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemophilia A Treatment Market, By Treatment Type:

• Factor Replacement Therapy
• Non-Factor Replacement Therapies
• Gene Therapy

Hemophilia A Treatment Market, By Route of Administration:

• Intravenous
• Oral
• Nasal

Hemophilia A Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Hemophilia A Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemophilia A Treatment Market.

Available Customizations:

Global Hemophilia A Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hemophilia A Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment Type (Factor Replacement Therapy, Non-Factor Replacement Therapies, Gene Therapy)
  • 4.2.2. By Route of Administration (Intravenous, Oral, Nasal)
  • 4.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment Type
  • 4.3.2. By Route of Administration
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. Asia Pacific Hemophilia A Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type
  • 5.2.2. By Route of Administration
  • 5.2.3. By Distribution Channel
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hemophilia A Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment Type
      • 5.3.1.2.2. By Route of Administration
      • 5.3.1.2.3. By Distribution Channel
  • 5.3.2. India Hemophilia A Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment Type
      • 5.3.2.2.2. By Route of Administration
      • 5.3.2.2.3. By Distribution Channel
  • 5.3.3. Australia Hemophilia A Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment Type
      • 5.3.3.2.2. By Route of Administration
      • 5.3.3.2.3. By Distribution Channel
  • 5.3.4. Japan Hemophilia A Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment Type
      • 5.3.4.2.2. By Route of Administration
      • 5.3.4.2.3. By Distribution Channel
  • 5.3.5. South Korea Hemophilia A Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment Type
      • 5.3.5.2.2. By Route of Administration
      • 5.3.5.2.3. By Distribution Channel

6. Europe Hemophilia A Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hemophilia A Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Germany Hemophilia A Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Spain Hemophilia A Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Italy Hemophilia A Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By Route of Administration
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. United Kingdom Hemophilia A Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By Route of Administration
      • 6.3.5.2.3. By Distribution Channel

7. North America Hemophilia A Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. Treatment Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hemophilia A Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Mexico Hemophilia A Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Canada Hemophilia A Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. South America Hemophilia A Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hemophilia A Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Argentina Hemophilia A Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Colombia Hemophilia A Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel

9. Middle East and Africa Hemophilia A Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hemophilia A Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Saudi Arabia Hemophilia A Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. UAE Hemophilia A Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hemophilia A Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Takeda Pharmaceutical Company Limited
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi Corporation
• 14.3. Genentech USA, Inc.
• 14.4. Novo Nordisk
• 14.5. Pfizer Inc.
• 14.6. CSL Behring LLC.
• 14.7. Grifols
• 14.8. Sagent Pharmaceuticals
• 14.9. Octapharma USA Inc.
• 14.10. UBI Pharma Inc

15. Strategic Recommendations

16. About Us & Disclaimer

관련자료